Here are four key points:
1. The procedure is FDA-approved, but still experimental.
2. However, it has been found to have a 90 percent-plus cure rate and is being increasingly adopted by healthcare providers.
3. In FMT, stool from a healthy donor’s system is transplanted into a C. diff patient’s colon.
4. The transplant can help reverse the bacterial imbalance that prevents the patient from fighting C. diff.
More articles on GI/endoscopy:
The latest advances in minimally invasive colorectal surgery
EndoChoice revenue leaps 27%: 5 things to know about Q2 financial results
55% of gastroenterologists will limit procedures for Medicare patients if colonoscopy cuts go into effect
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
